Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044447 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
A Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT00044447: Completed Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Sanofi.
NCT00044447 is a Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent that has completed, run by Sanofi. The registered enrollment target is 170 participants, below the 210-participant average among 5 other Diabetes Mellitus, Non-Insulin-Dependent trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044447, a Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.
Conditions Studied
Interventions
- DRUG Glimepiride
Study Locations (1)
Texas
- Dallas Diabetes & Endocrine Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2001-05 |
| Est. Completion | 2002-09 |
| Phase | Phase 3 |
What the finished NCT00044447 record still lists
NCT00044447 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 210-participant average among 5 other Diabetes Mellitus, Non-Insulin-Dependent trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Diabetes Mellitus, Non-Insulin-Dependent appearing as the primary indexed condition, and to 1 intervention - of which Glimepiride is the first listed.
NCT00044447 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00044447 about?
NCT00044447 is a clinical study titled "Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione". The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.
What is the current status of trial NCT00044447?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2001-05. Estimated completion is 2002-09.
What conditions does trial NCT00044447 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Non-Insulin-Dependent.
What interventions are being tested in trial NCT00044447?
The interventions under investigation include: Glimepiride (DRUG).
Who is sponsoring clinical trial NCT00044447?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00044447 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Non-Insulin-Dependent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
COMPLETED · Phase 3
-
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
COMPLETED · Phase 1
-
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
COMPLETED · Phase 4
-
Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes
COMPLETED · NA
-
Study of the Effects of Vitamin C on Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
Methods for Measuring Insulin Sensitivity
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia